Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-233-8 | CAS number: 104-75-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- as of 1997
- Principles of method if other than guideline:
- HPRT assay for the detection of mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus (6-thioguanine [6TG] resistance) in mouse lymphoma cells using a fluctuation protocol according to Cole et al. 1983.
Reference:
Cole J, Arlett C F, Green M H L, Lowe J and Muriel W 1983: A comparison of the agar cloning and microtitration techniques for assaying cell survival and mutation frequency in L5178Y mouse lymphoma cells. Mutation Research, 111, 317-386 - GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- other: mammalian cell gene mutation assay
Test material
- Reference substance name:
- Octylamine
- EC Number:
- 203-916-0
- EC Name:
- Octylamine
- Cas Number:
- 111-86-4
- Molecular formula:
- C8H19N
- IUPAC Name:
- octan-1-amine
Constituent 1
Method
- Target gene:
- Induction of a forward mutation in the X-linked hprt locus: Resistance to the toxic analogue 6-thioguanine (6TG) results from lack of hypoxanthine-guanine phosphoribosyl transferase (HPRT) activity. Thus, the hprt-negative mutants are unable to use 6TG and survive in its presence.
Species / strain
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI media (containing antibiotics and varying concentrations of horse serum, heat-inactivated, from 0 - 20 %)
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically "cleansed" against high spontaneous background: yes,
- Other procedures: purge of TK-negative mutants - Additional strain / cell type characteristics:
- other: TK proficient (TK+)
- Metabolic activation:
- with and without
- Metabolic activation system:
- post-mitochondrial fraction from livers of male SD rats previously induced with Arochlor-1254
- Test concentrations with justification for top dose:
- Experiment 1: 0, 10, 20, 30, 40, 50, 60, 70, 75, 80, 90, 100 µg/mL (evaluated)
Experiment 2: 0, 10, 20, 30, 40, 50, 55, 60, 65, 70, 72.5, 75, 80, 90 µg/mL (evaluated) - Vehicle / solvent:
- - Vehicle/solvent used: DMSO
- Justification for choice of solvent/vehicle: sufficient water solubility of the test substance
Controls
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO, diluted 100-fold in treatment medium
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 4-nitroquinoline-N-oxide (-S9); benzo(a)pyrene (+S9)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium, incubation in centrifuge tubes, culture flasks, and wells of microtiter plates, depending on the operation step
DURATION
- Preincubation period: no data, pre-culture in RPMI 10 after thawing up to an appropriate cell density
- Exposure duration: 3 h
- Incubation temperature: 37 +- 1 °C
- Expression time (cells in growth medium): 7 d
- Selection time: 12 to 13 d
SELECTION AGENT: 6-thioguanine (6-TG)
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: Selection of 6-TG resistance: 4 microtiter plates of 96 wells each; at 2 x10^4 cells per well each
(= 384 x 2 x10^4 cells per test concentration)
DETERMINATION OF CYTOTOXICITY
- Method: Relative survival in the presence and absence of test substance (by visual counting of viable clones in microtiter plates)
DETERMINATION of VIABILITY (after expression period)
- Method: visual counting of viable clones in microtiter plates
DETERMINATION of 6-TG RESISTANCE (after expression period)
- Method: visual inspection of microtiter plates for the number wells containing clones. - Evaluation criteria:
- ACCEPTANCE CRITERIA
The assay was considered valid if the following criteria were met:
1. the mutant frequencies in the negative (vehicle) control cultures fell within the normal range (not more than three times the historical mean value)
2. at least one concentration of each of the positive control chemicals induced a clear increase in mutant frequency (the difference between the positive and negative control mutant frequencies was greater than half the historical mean value).
EV ALUATION CRITERIA
For valid data, the test article was considered to induce forward mutation at the hprt locus in mouse lymphoma L5178Y cells if:
1. the mutant frequency at one or more concentrations was significantly greater than that of the negative control (p < 0.05)
2. there was a significant concentrationrelationship as indicated by the linear trend analysis (p < 0.05)
3. the effects described above were reproducible.
Results that only partially satisfied the assessment criteria described above were considered on a case-by-case basis. - Statistics:
- Statistical significance of mutant frequencies was carried out according to the UKEMS guidelines. Thus the control log mutant frequency (LMF) was compared with the LMF from each treatment concentration, and secondly the data were checked for a linear trend in mutant frequency with test article treatment. These tests require the calculation of the heterogeneity factor to obtain a modified estimate of variance.
Reference:
Robinson et al. 1990: Statistical evaluation of bacterial/mammalian fluctuation tests. In Statistical Evaluation of Mutagenicity Test Data (Ed D J Kirkland), Cambridge University Press, pp 102 – 140.
Results and discussion
Test results
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- dose-related: The highest concentration to reliably provide >10 % RS was 40.41 µg/mL in the absence and 80.81 µg/mL in the presence of S9.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: marked increases of >= 1 pH unit at >= 1293 µg/mL
- Effects of osmolality: no
- Evaporation from medium: no
- Precipitation: no
RANGE-FINDING/SCREENING STUDIES: for cytotoxicity testing up to 1293 µg/mL
COMPARISON WITH HISTORICAL CONTROL DATA: Acceptance criterion, Control/Historical ratio > 0.5, fulfilled for positive controls
(See Appendices)
Any other information on results incl. tables
Summary of mutation data [table 8; means of two replicate cultures]
Experiment 1 (3 hour treatment in the absence and presence of S-9)
[for individual replicates, see Appendix 2, Table 10 (-S9), and Appendix 3, Table 18 (+S9)]
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||
|
% RS |
MF§ |
|
|
% RS |
MF§ |
|
0 |
100 |
5.84 |
|
0 |
100 |
3.74 |
|
20 |
86 |
6.48 |
NS |
20 |
92 |
3.07 |
NS |
30 |
68 |
5.98 |
NS |
30 |
89 |
2.46 |
NS |
40 |
46 |
7.90 |
NS |
40 |
73 |
3.42 |
NS |
50 |
43 |
7.15 |
NS |
50 |
55 |
3.37 |
NS |
60 |
18 |
5.93 |
NS |
60 |
43 |
5.09 |
NS |
|
|
|
|
70 |
24 |
2.22 |
NS |
|
|
|
|
75 |
12 |
2.11 |
NS |
Linear trend |
NS |
Linear trend |
NS |
||||
NQO |
|
|
|
B[a]P |
|
|
|
0.1 |
63 |
19.94 |
|
2 |
63 |
48.97 |
|
0.15 |
52 |
30.99 |
|
3 |
19 |
163.83 |
|
Experiment 2 (3 hour treatment in the absence and presence of S-9)
[for individual replicates, see Appendix 4, Table 26 (-S9), and Appendix 5, Table 34 (+S9)]
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||
|
% RS |
MF§ |
|
|
% RS |
MF§ |
|
0 |
100 |
4.98 |
|
0 |
100 |
4.40 |
|
10 |
86 |
4.14 |
NS |
20 |
93 |
4.88 |
NS |
20 |
59 |
4.09 |
NS |
40 |
65 |
3.14 |
NS |
30 |
48 |
3.48 |
NS |
50 |
52 |
3.26 |
NS |
40 |
41 |
4.40 |
NS |
60 |
42 |
1.82 |
NS |
50 |
34 |
1.88 |
NS |
65 |
40 |
2.42 |
NS |
55 |
30 |
2.47 |
NS |
70 |
35 |
3.63 |
NS |
60 |
22 |
4.61 |
NS |
80 |
38 |
2.57 |
NS |
65 |
10 |
4.69 |
NS |
90 |
22 |
2.76 |
NS |
Linear trend |
NS |
Linear trend |
NS |
||||
NQO |
|
|
|
B[a]P |
|
|
|
0.1 |
33 |
28.54 |
|
2 |
46 |
31.06 |
|
0.15 |
31 |
16.57 |
|
3 |
28 |
69.69 |
|
§ = 6TG resistant mutants/106viable cells 7 days after treatment
% RS =Percent relative survival adjusted by post treatment cell counts
NS = not significant
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.